This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|August 3, 2021
FDA Launches New Crowdsourcing Challenge for Pediatric Research Questions
Author(s)BioPharm International Editors
FDA is launching a new crowdsourcing challenge to solicit ideas for pediatric research.
Advertisement
On August 2, 2021, the FDA’s Division of Pediatrics and Maternal Health (DPMH) launched the “Send Your Pediatric Research Questions to the FDA” campaign. The goal of this challenge is to crowdsource new ideas for internal pediatric research.
FDA’s pooled analyses have investigated relationships between biomarkers and different clinical endpoints in regulatory submissions, explored the use of novel trial designs in small populations, and deepened understanding of how adult efficacy data can be extrapolated. The DPMH hopes to accelerate findings of this nature through the crowdsource campaign.
Following the end of the challenge, all submissions will be reviewed and the DPMH may select one or more questions for future use in internal research projects. However, those who submit these questions will not be granted access or be allowed to collaborate in these research studies.
Submissions must be received by August 20, 2021. For more information about submission guidelines, visit DPMH’s site at https://shareyourvoice.ideascalegov.com.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5